After the Breakthrough: Why Veteran Healing Needs Reintegration, Not Just Treatment

For many veterans, the hardest part of healing does not end when treatment ends. It begins when they come home.

For someone living with post-traumatic stress, traumatic brain injury, substance use challenges, depression, anxiety, or the invisible weight of military service, a breakthrough can be powerful. It can create space. It can open a door that felt locked for years. It can help someone feel hope again.

But a breakthrough is not the same thing as a rebuilt life.

That distinction matters, especially as new research around ibogaine and other psychedelic-assisted therapies continues to gain attention in the veteran mental health space. Early findings are promising. Public research initiatives are expanding. Families are paying attention. Veterans are asking hard questions about what healing could look like when traditional care has not been enough.

But if the conversation stops at the treatment itself, we miss the part that may matter most.

It has to become a morning routine, a calmer conversation with a spouse, a different response to stress, a new relationship with the body, a better night of sleep, a reason to stay connected, and a way to carry the past without being trapped inside it.

That is where reintegration begins.

The invisible battle after service

Military service can leave marks that are difficult to explain to people who have not lived it. Some are physical. Some are neurological. Some are emotional. Some show up years later as anger, numbness, isolation, substance use, sleep disruption, panic, depression, or a sense of being disconnected from the person someone used to be.

The scale of the need is real.

Those numbers are not just statistics. They point to a deeper truth: many veterans are still carrying pain outside the reach of traditional systems.

That does not mean existing treatments do not help. Many do. Evidence-based therapies, medication, peer support, family support, crisis care, and VA services save lives every day. But for some veterans — especially those with complex trauma, traumatic brain injury, or long-standing substance use — the path can be harder, longer, and less linear.

This is why new approaches are being studied with urgency.

Why ibogaine is part of the conversation

Ibogaine is a psychoactive compound derived from the iboga shrub, traditionally associated with spiritual and healing practices in Central Africa. In modern research settings, it is being studied for potential effects on substance use disorders, traumatic brain injury, PTSD, depression, anxiety, and related conditions.

The most widely discussed veteran-focused study came from Stanford Medicine and was published in Nature Medicine in 2024. In that prospective observational study, 30 male Special Operations Forces veterans with predominantly mild traumatic brain injury received a magnesium-ibogaine protocol in Mexico, where ibogaine treatment is legally available. The study found statistically significant improvements in functioning, PTSD, depression, and anxiety one month after treatment, with no unexpected or serious adverse events reported in the study setting.

The results were striking.

That kind of data is why the field is paying attention.

But the caution matters just as much as the promise. The Stanford study was not a randomized controlled trial, the sample was small and highly specific, and participants had independently chosen to travel internationally for treatment. The authors were clear that larger controlled trials are needed and that factors beyond ibogaine itself — including complementary therapies, group experiences, expectation, and return-home stressors — may have influenced outcomes.

A 2022 systematic review of ibogaine and noribogaine research looked at 24 studies including 705 individuals. The review found that published data suggest ibogaine may reduce withdrawal symptoms and craving in substance use disorders, and may also have beneficial effects on depressive and trauma-related symptoms. But it also noted severe medical complications and deaths, including two fatalities described in the studies reviewed, and concluded that rigorous medical settings, monitoring, and further research are necessary.

This is why the phrase "medically supervised" matters. Ibogaine is not a wellness shortcut. It is a powerful intervention under investigation, with real risks — especially cardiac risks — that require careful screening and monitoring.

The research momentum is growing

The national conversation is shifting from anecdote to structured research.

In Texas, UTHealth Houston and UTMB Health were awarded $50 million from the Texas Health and Human Services Commission to lead a two-year, multicenter trial evaluating ibogaine for addiction, traumatic brain injury, and other behavioral health conditions. The statewide partnership, called IMPACT, includes multiple Texas institutions, with UT Austin and Baylor College of Medicine focusing specifically on traumatic brain injury, particularly in veterans.

At the federal level, the FDA announced new actions in April 2026 to support development of psychedelic-related medications for serious mental illness, including PTSD, depression, and substance use disorders. Those actions included priority vouchers for companies studying psychedelic-related treatments and clearance for an early phase U.S. clinical study of noribogaine hydrochloride, a derivative of ibogaine, for alcohol use disorder. Importantly, the FDA also emphasized that allowing a study to proceed does not mean the drug has been approved or found to be safe or effective.

That nuance is essential. The door is opening for more rigorous research, but research is not the same as access, approval, or universal safety.

Still, the momentum reflects something meaningful: the system is beginning to take seriously what many veterans and families have been saying for years. There are people who need more options.

Why the breakthrough is only the beginning

One of the clearest lessons from psychedelic-assisted therapy research is that the medicine is not the whole model.

In many clinical protocols, the intervention is built around preparation, the dosing session itself, and integration afterward. A 2024 implementation science paper on psychedelic-assisted therapy described most protocols as including preparation sessions, a dosing session, and integration sessions for processing and meaning-making after the experience. The VA's National Center for PTSD similarly describes psychedelic-assisted therapy as an approach where the medicine, psychotherapy component, participant mindset, and therapeutic setting interact together.

In plain language, integration means helping someone answer a very human question:

That is the gap Tony Glace, founder of One & Done, kept coming back to during his conversation on the Living Undeterred podcast. He described plant medicine as only "10 to 20% of the process," with the rest being integration — because many veterans return home after treatment with limited follow-up and limited support for the daily work of change.

That is a powerful insight because it shifts the focus from the moment of treatment to the life that follows.

Why family reintegration matters

Healing does not happen in isolation.

When a veteran comes home changed, the family has to understand that change too. A spouse may not know what to expect. Children may sense that something is different but not know how to talk about it. Old patterns may still be waiting at the front door. Stress, financial pressure, sleep problems, parenting dynamics, and emotional distance can all return quickly if the home environment is not supported.

The VA's National Center for PTSD notes that PTSD affects the broader social network around a person, and that the health of that social network can influence the development, maintenance, or recovery of PTSD. It also notes that positive social support can buffer the severity of PTSD and may contribute to a more successful course of trauma treatment.

That is why family-inclusive support is more than a nice add-on. It can be part of the recovery environment.

Tony made this point directly in the podcast. He described the need to bring spouses or significant others into the integration process because some veterans were returning home "completely transformed," while their families did not recognize the change or know how to relate to it.

One & Done's role in the ecosystem

One & Done is building around that missing middle.

The organization describes its mission as helping U.S. military veterans and their families translate breakthrough experiences into durable, everyday recovery. Its model focuses on structured, non-clinical residential reintegration support in Texas following medically supervised treatment abroad.

Their three-pillar approach centers on practice, payment, and policy: residential reintegration support, scholarship-style access through the Veterans Healing Fund, and outcomes measurement with standards-focused education. The model includes structured routines, peer support, re-entry planning, family-inclusive support where appropriate, continuity with existing care teams, escalation to licensed providers when needed, and outcomes tracking over time.

Just as important, One & Done is clear about its boundaries. The organization states that it does not administer substances or prescribe medications, and that no controlled substances are stored, dispensed, or used at any One & Done site.

That distinction is critical. One & Done is not trying to replace medical treatment. It is trying to support what comes after it.

Recovery is a life, not a moment

The Substance Abuse and Mental Health Services Administration defines recovery as a process of change through which people improve health and wellness, live self-directed lives, and strive to reach their full potential. SAMHSA also identifies four major dimensions of recovery:

This is where the missions of One & Done and Brightn quietly overlap.

One & Done is focused on helping veterans translate breakthrough experiences into durable recovery through structure, family support, reintegration, and long-term healing. Brightn is focused on upstream mental wellness — helping people build awareness and resilience through reflective journaling, emotional trend recognition, and daily tools that support consistency between moments of care.

They are not the same organization. They are not doing the same work. But they are participating in the same larger mission: helping people move from crisis response to daily support, from isolated moments of help to ongoing practices of healing, from surviving to rebuilding.

For veterans carrying the invisible wounds of service, the future of care should not be limited to asking, "What treatment might help?"

It should also ask, "What support will help that healing last?"

That is the work ahead. And it is work worth building.